Effect of omega-3 fatty acid supplementation on arterial elasticity in patients with familial hypercholesterolaemia on statin therapy

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 26, Issue 12, 2016, Pages 1140-1145

  Chan, D C ^a   Pang, J ^a   Barrett, P H R ^a,b   Sullivan, D R ^c   Mori, T A ^a   Burnett, J R ^a,d   van Bockxmeer, F M ^b,d   Watts, G F ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d FIONA STANLEY HOSPITAL   (Australia)

Author keywords

Atherosclerosis; Cardiovascular disease; Diet and nutrition; Genetics; Hypercholesterolaemia; Vascular dysfunction

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; EZETIMIBE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; ROSUVASTATIN; SIMVASTATIN; STATIN (PROTEIN); TRIACYLGLYCEROL; APOB PROTEIN, HUMAN; APOLIPOPROTEIN B100; BIOLOGICAL MARKER; DOCOSAHEXAENOIC ACID; DRUG COMBINATION; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; OMEGA 3 ACID ETHYL ESTER;

ADULT; AGED; ARTERIAL STIFFNESS; ARTICLE; ATRIAL FIBRILLATION; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PRIORITY JOURNAL; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; ARTERIAL PRESSURE; BLOOD; CARDIOVASCULAR DISEASES; CROSSOVER PROCEDURE; DIETARY SUPPLEMENT; DRUG COMBINATION; DRUG EFFECTS; HYPERLIPOPROTEINEMIA TYPE II; MIDDLE AGED; PATHOPHYSIOLOGY; TIME FACTOR; TREATMENT OUTCOME; WESTERN AUSTRALIA;

APOLIPOPROTEIN B-100; ARTERIAL PRESSURE; BIOMARKERS; CARDIOVASCULAR DISEASES; CROSS-OVER STUDIES; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DRUG COMBINATIONS; EICOSAPENTAENOIC ACID; EZETIMIBE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; VASCULAR STIFFNESS; WESTERN AUSTRALIA;

EID: 84995467664     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2016.07.012     Document Type: Article

References (35)

1. [1] Goldstein, J.L., Brown, M.S., Regulation of low-density lipoprotein receptors: implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis. Circulation 76 (1987), 504–507.
2. [2] Austin, M.A., Hutter, C.M., Zimmern, R.L., Humphries, S.E., Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol 160 (2004), 421–429.
3. [3] Nordestgaard, B.G., Chapman, M.J., Humphries, S.E., Ginsberg, H.N., Masana, L., Descamps, O.S., et al., European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus Statement of the European Atherosclerosis Society. Eur Heart J 34 (2013), 3478–3490.
4. [4] Lusis, A.J., Atherosclerosis. Nature 407 (2000), 233–241.
5. [5] Chan, D.C., Pang, J., Hooper, A.J., Burnett, J.R., Bell, D.A., Bates, T.R., et al. Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia. Int J Cardiol 201 (2015), 633–638.
6. [6] Duprez, D.A., Jacobs, D.R., Lutsey, P.L., Bluemke, D.A., Brumback, L.C., Polak, J.F., et al. Association of small artery elasticity with incident cardiovascular disease in older adults: the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol 174 (2011), 528–536.
7. [7] Wilkins, J.T., McDermott, M.M., Liu, K., Chan, C., Criqui, M.H., Lloyd-Jones, D.M., Associations of noninvasive measures of arterial compliance and ankle-brachial index: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Hypertens 25 (2012), 535–541.
8. [8] Duprez, D.A., De Buyzere, M.M., De Bruyne, L., Clement, D.L., Cohn, J.N., Small and large artery elasticity indices in peripheral arterial occlusive disease (PAOD). Vasc Med 6 (2001), 211–214.
9. [9] Grey, E., Bratteli, C., Glasser, S.P., Alinder, C., Finkelstein, S.M., Lindgren, B.R., et al. Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular events. Am J Hypertens 16 (2003), 265–269.
10. [10] Mori, T.A., Beilin, L.J., Long-chain omega 3 fatty acids, blood lipids and cardiovascular risk reduction. Curr Opin Lipidol 12 (2001), 11–17.
11. [11] Mozaffarian, D., Wu, J.H.Y., (n-3) fatty acids and cardiovascular Health: are effects of EPA and DHA shared or complementary?. J Nutr 142 (2012), 614S–625S.
12. [12] Hill, A.M., Buckley, J.D., Murphy, K.J., Howe, P.R.C., Combining fish-oil supplements with regular aerobic exercise improves body composition and cardiovascular disease risk factors. Am J Clin Nutr 85 (2007), 1267–1274.
13. [13] Meyer, B.J., Hammervold, T., Rustan, A.C., Howe, P.R., Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects. Lipids 42 (2007), 109–115.
14. [14] Wang, S., Ma, A.Q., Song, S.W., Quan, Q.H., Zhao, X.F., Zheng, X.H., Fish oil supplementation improves large arterial elasticity in overweight hypertensive patients. Eur J Clin Nutr 62 (2008), 1426–1431.
15. [15] Sjoberg, N.J., Milte, C.M., Buckley, J.D., Howe, P.R., Coates, A.M., Saint, D.A., Dose-dependent increases in heart rate variability and arterial compliance in overweight and obese adults with DHA-rich fish oil supplementation. Br J Nutr 103 (2010), 243–248.
16. [16] McVeigh, G.E., Brennan, G.M., Cohn, J.N., Finkelstein, S.M., Hayes, R.J., Johnston, G.D., Fish oil improves arterial compliance in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 14 (1994), 1425–1429.
17. [17] Wong, A.T.Y., Chan, D.C., Barrett, P.H.R., Adams, L.A., Watts, G.F., Wong ATY Supplementation with n3 fatty acid ethyl esters increases large and small arterial elasticity in obese adults on a weight loss diet. J Nutr 143 (2013), 43–441.
18. [18] Mori, T.A., Burke, V., Puddey, I., Irish, A., Cowpland, C.A., Beilin, L., et al. The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial. J Hypertens 27 (2009), 1863–1872.
19. [19] Pase, M.P., Grima, N.A., Sarris, J., Do long-chain n-3 fatty acids reduce arterial stiffness? A meta-analysis of randomized controlled trials. Br J Nutr 106 (2011), 974–980.
20. [20] GISSI-Prevenzione Investigators, Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354 (1999), 447–455.
21. [21] Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369 (2007), 1090–1098.
22. [22] Kris-Etherton, P.M., Harris, W.A., Appel, L.J., Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106 (2002), 2747–2757.
23. [23] Zimlichman, R., Shargorodsky, M., Boaz, M., Duprez, D., Rahn, K.H., Rizzonl, D., et al. Determination of arterial compliance using blood pressure waveform analysis with the CR-2000 system: Reliability, repeatability, and establishment of normal values for healthy European population—the seven European sites study (SESS). Am J Hypertens 18 (2005), 65–71.
24. [24] Friedewald, W.T., Levy, R.I., Fredrickson, D.S., Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972), 499–502.
25. [25] Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985), 412–419.
26. [26] Woodman, R.J., Kingwell, B.A., Beilin, L.J., Hamilton, Se, Dart, A.M., Watts, G.F., Assessment of central and peripheral arterial stiffness: studies indicating the need to use a combination of techniques. Am J Hypertens 18 (2005), 249–260.
27. [27] Najjar, S.S., Scuteri, A., Lakatta, E.G., Arterial aging: is it an immutable cardiovascular risk factor?. Hypertension 46 (2005), 454–462.
28. [28] Zieman, S.J., Melenovsky, V., Kass, D.A., Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 25 (2005), 932–943.
29. [29] Mori, T.A., Omega-3 fatty acids and cardiovascular disease: epidemiology and effects on cardiometabolic risk factors. Food Funct 5 (2014), 2004–2019.
30. [30] McVeigh, G.E., Brennan, G.M., Johnston, G.D., McDermott, B.J., McGrath, L.T., Henry, W.R., et al. Dietary fish oil augments nitric oxide production or release in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 36 (1993), 33–38.
31. [31] von Schacky, C., Kiefl, R., Jendraschak, E., Kaminski, W.E., n-3 fatty acids and cysteinyl-leukotriene formation in humans in vitro, ex vivo, and in vivo. J Lab Clin Med 121 (1993), 302–309.
32. [32] Serhan, C.N., Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not?. Am J Pathol 177 (2010), 1576–1591.
33. [33] Segers, P., Oasem, A., De Backer, T., Carlier, S., Verdonck, P., Avolio, A., Peripheral “oscillatory” compliance is associated with aortic augmentation index. Hypertension 37 (2001), 1434–1439.
34. [34] Chemla, D., Hébert, J.L., Coirault, C., Zamani, K., Suard, I., Colin, P., et al. Total arterial compliance estimated by stroke volume-to-aortic pulse pressure ratio in humans. Am J Physiol Heart Circ Physiol 274 (1998), 500–505.
35. [35] Resnick, L.M., Militianu, D., Cunnings, A.J., Pipe, J.G., Evelhoch, J.L., Soulen, R.L., et al. Pulse waveform analysis of arterial compliance: relation to other techniques, age, and metabolic variables. Am J Hypertens 13 (2000), 1243–1249.